Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.

Kato, Yuka

Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. [electronic resource] - Cancer science Oct 2018 - 3149-3158 p. digital

Publication Type: Journal Article

1349-7006

10.1111/cas.13752 doi


Anilides--pharmacology
Animals
Antigens, Differentiation, B-Lymphocyte--genetics
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Carcinoma, Non-Small-Cell Lung--drug therapy
Cell Line, Tumor
Crizotinib
Drug Resistance, Neoplasm--genetics
ErbB Receptors--metabolism
Female
Gefitinib
Heparin-binding EGF-like Growth Factor--metabolism
Histocompatibility Antigens Class II--genetics
Humans
Lung Neoplasms--drug therapy
Mice
Mice, Inbred NOD
Oncogene Proteins, Fusion--genetics
Protein Kinase Inhibitors--pharmacology
Protein-Tyrosine Kinases--antagonists & inhibitors
Proto-Oncogene Proteins--antagonists & inhibitors
Pyrazoles--pharmacology
Pyridines--pharmacology
Quinazolines--pharmacology
Receptor Protein-Tyrosine Kinases--metabolism
Sodium-Phosphate Cotransporter Proteins, Type IIb--genetics
Up-Regulation
Xenograft Model Antitumor Assays
Axl Receptor Tyrosine Kinase